LUNG
$1.62
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Recent News
Pulmonx Corporation Q4 2025 Earnings Call Summary
Moby summary of Pulmonx Corporation's Q4 2025 earnings call
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Sales Force ...
Pulmonx Corp (LUNG) focuses on cost efficiency and sales team optimization to drive future growth despite current revenue declines.
Pulmonx Q4 Earnings Call Highlights
Pulmonx (NASDAQ:LUNG) executives said the company is entering 2026 focused on rebuilding U.S. momentum, advancing clinical programs designed to expand its total addressable market, and tightening spending to improve operating leverage, following what management described as a weaker-than-expected U.
Pulmonx (LUNG) Q4 2025 Earnings Call Transcript
Earlier today, Pulmonx Corporation issued a press release announcing its financial results for the quarter ended 12/31/2025. A copy of the press release is available on the Pulmonx Corporation website at investors.pulmonx.com. Before we begin, I would like to remind you that management will make statements during the call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +35.90% and +3.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?